CDA-AMC compresses the clock: a 180-day review quietly reorders launch sequencing
A procedural reform to the reimbursement-review timeline reads like inside baseball. It actually moves the starting gun on every downstream channel event — pCPA negotiation, provincial listing, launch sequencing — earlier by months.
CDA-AMC consulted on a streamlined reimbursement-review process under which it would initiate a review and publish a final recommendation within 180 calendar days, paired with new reconsideration and resubmission procedures, beginning with applications targeting the December 2026 expert-committee meetings.
Canada's drug-access pathway is a relay, and the slowest leg has often been the gap between a manufacturer's submission and a final reimbursement recommendation. CDA-AMC's proposed overhaul targets that leg directly. The agency consulted on a streamlined process under which it initiates a review and publishes a final recommendation within 180 calendar days, paired with new reconsideration and resubmission procedures, for applications targeting the December 2026 expert-committee meetings and beyond.
Create a free account to read the full interpretation.
You’ve reached the part where The Indication earns its name — the read on distribution, reimbursement timing, and channel strategy. It’s free to finish: sign in or create an account to keep reading every analysis in full.